Kodiak Sciences (BMV:KOD *) - Cotización, noticias y análisis

Resumen de acción KOD *

A clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases.

Acerca de la empresa

Análisis fundamental de KOD *
Puntuación del snowflake
Valoración	2/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	6/6
Dividendos	0/6

Recompensas

Análisis de riesgos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Acciones altamente ilíquidas

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Kodiak Sciences Inc.

Genomma Lab Internacional. de

BMV:LAB B

Mex$21.2b

Enanta Pharmaceuticals

NasdaqGS:ENTA

US$221.8m

Genfit

ENXTPA:GNFT

€257.5m

ImmuneOnco Biopharmaceuticals (Shanghai)

SEHK:1541

HK$2.3b

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Kodiak Sciences
Precios históricos de las acciones
Precio actual de la acción	US$148.04
Máximo en las últimas 52 semanas	US$205.00
Mínimo de 52 semanas	US$160.13
Beta	1.77
1Cambio en 1 mes	0%
Variación en 3 meses	n/a
Cambio de 1 año	n/a
3Variación en 3 años	n/a
Variación en 5 años	n/a
Variación desde la OPV	-89.12%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	KOD *	MX Biotechs	Mercado MX
7D	0%	0%	0%
1Y	n/a	0%	0%

Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de KOD * en comparación con el sector MX Biotechs .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de KOD * frente al mercado MX.

Volatilidad de los precios

Is KOD *'s price volatile compared to industry and market?
KOD * volatility
KOD * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Precio estable de las acciones: KOD * no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de KOD * en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2009	112	Victor Perlroth	kodiak.com

Resumen de fundamentos de Kodiak Sciences Inc.

¿Cómo se comparan los beneficios e ingresos de Kodiak Sciences con su capitalización de mercado?
Estadísticas fundamentales de KOD *
Capitalización bursátil	Mex$4.32b
Beneficios(TTM)	-Mex$6.03b
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-0.7x

Ratio precio-beneficio (PE)

¿Está KOD * sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de KOD *
Ingresos	US$0
Coste de los ingresos	US$0
Beneficio bruto	US$0
Otros gastos	US$333.82m
Beneficios	-US$333.82m

Últimos beneficios comunicados

Dec 31, 2022

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-6.41
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado KOD * a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción KOD *

Recompensas

Análisis de riesgos

Competidores de Kodiak Sciences Inc.

BMV:LAB B

Mex$21.2b

NasdaqGS:ENTA

US$221.8m

ENXTPA:GNFT

€257.5m

SEHK:1541

HK$2.3b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Kodiak Sciences Inc. Announces Executive Appointments

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

Recent updates

Kodiak Sciences Inc. Announces Executive Appointments

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Kodiak Sciences Reports Positive Topline Results from Beacon Phase 3 Study of Tarcocimab Tedromer (Ksi-301) in Patients with Retinal Vein Occlusion

Kodiak Sciences Inc. Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell 2000 Growth Index

Co-Founder recently sold Mex$251m worth of stock

Kodiak Sciences Inc. Announces Top-Line Results from Its Initial Phase 2B/3 Study of KSI-301 in Patients with Neovascular Age-Related Macular Degeneration

Kodiak Sciences Inc. Completes Enrollment in Gleam and Glimmer Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Kodiak Sciences Inc. Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Forecast to breakeven in 2025

Forecast to breakeven in 2024

Kodiak Sciences Inc. Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1B Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. to Report Q3, 2020 Results on Nov 09, 2020

Kodiak Sciences Inc. Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Kodiak Sciences Inc.

0.0x

-0.7x

Beneficios e Ingresos